Recent News Releases

Home to CSL’s manufacturing site since the 1950s, funding will support the urgent needs of residents and rebuilding and restoration efforts KING OF PRUSSIA, PA, USA – March 30, 2026 — CSL...

Dear Hemophilia B Community, We are writing to share an important update on the availability of HEMGENIX® (etranacogene dezaparvovec-drlb). CSL is currently experiencing a temporary global...

CSL Seqirus will supply its differentiated influenza vaccine portfolio and, with long-term partner Sinergium Biotech, will localize vaccine filling and distribution. The partnership will...

New $1.5 billion investment builds on over $3 billion already spent on CSL's U.S. operations since 2018 Expansion will create at least 300 new jobs and enhance production of plasma-derived...

FOR GLOBAL MEDIA CSL Seqirus will provide adjuvanted cell-based vaccines to support Canada, if an influenza pandemic is declared by the World Health Organization (WHO) Influenza viruses of...

Melbourne, 16 February 2026 CSL Seqirus, part of leading Australian biotechnology company CSL, has today announced that neffy® adrenaline (epinephrine) nasal spray is now available and has been...

- 94% of patients (51 of 54) remained free from the burden of continuous prophylaxis treatment through five years following a single infusion of HEMGENIX, demonstrating sustained therapeutic...

Australia’s onshore vaccine manufacturing capabilities took a leap forward today as The Hon Mark Butler MP, Minister for Health, Disability and Ageing,...

Builds on company’s more than $3b U.S. investment since 2018 which created thousands of new jobs across 44 states

Thursday 30 October, Riyadh – CSL Seqirus and Vaccine Industrial Company, have signed a Memorandum of Understanding with the Ministry of Health of Saudi Arabia to enhance the biotechnology...

Could we all have lifelong robust immunity? Dr Carolien van de Sandt, Murdoch Children’s Research Institute, Melbourne Making proteins with AI: Dr Rhys Grinter, Bio21 Institute, The University...

Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing BROADMEADOWS, AUSTRALIA, Oct....

INTENDED FOR MEDIA AND BUSINESS INVESTORS ONLY Summit, New Jersey, USA | 21 October, 2025 – CSL Seqirus, a global leader in seasonal influenza prevention (ASX: CSL), has shared new actionable...

Summit, New Jersey, USA | 17 October 2025 – CSL Seqirus, a business of CSL (ASX:CSL) today announced that it will be presenting 14 abstracts at the European Scientific Working group on Influenza...

Melbourne, Australia – CSL has announced that the Science Based Targets initiative (SBTi) has approved CSL’s near-term science-based emissions reduction targets. These are:...

CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for the...

FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor...

Melbourne, Australia – 16 September 2025 CSL today announced it has entered into a strategic collaboration with privately held Dutch biotech company VarmX BV to support the company’s...

Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit...

Global biotherapeutics leader CSL today announced a reported net profit after tax of US$3.0 billion for the 12 months ended 30 June 2025, up 17% on a constant currency basis. Underlying profit...

ANDEMBRY is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in people with HAE The authorization of ANDEMBRY expands CSL's HAE franchise and...

ANDEMBRY inhibits the top of the HAE cascade by targeting factor XIIa and provides sustained protection from attacks Once-monthly dosing reduced HAE attacks by a median of more than 99 percent and...

First non-immunosuppressive dual-action therapy recommended by NICE for eligible patients with IgA nephropathy, a leading cause of kidney failure 1-3 NICE's recommendation is based on clinically...

CSL Behring’s new facility in Broadmeadows, Victoria, has been named the 2025 Facility of the Year by the International Society for Pharmaceutical Engineering (ISPE), in the Pharma 4.0 category....

CSL Seqirus to provide pandemic influenza vaccine to support 17 EU and EEA countries and the EU Commission in the event of a pandemic declaration. The decision by the Health Emergency Preparedness...

European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN) Decision follows positive...

ANDEMBRY® received manufacturing and marketing approval in Japan on February 20, 2025, for the prevention of acute attacks in hereditary angioedema (HAE) ANDEMBRY® is the first-in-class...

To date, there have been over 46,300 lab-confirmed influenza cases in Australia, more than 50% higher than the previous record of flu cases in Australia during the first quarter (January – March...

Melbourne, 2 April 2025 – Australian healthcare company CSL has launched the CSL Community Impact Awards, a new initiative designed to support not-for-profit community organisations focused on...

Melbourne, 4 March 2025 – CSL Seqirus and Esperion Therapeutics have today announced the signing of an exclusive license and distribution agreement to commercialize Nexletol® (bempedoic acid)...

ANDEMBRY® is the first and only once-monthly treatment targeting factor XIIa to prevent recurrent attacks in HAE patients. The approval marks the fifth regulatory approval of ANDEMBRY,...

ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation...

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to 12 months post-vaccination compared to conventional...

- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading...

94 percent of patients eliminated factor IX prophylaxis and remained free of continuous prophylaxis through four years post-treatment Mean factor IX activity levels were sustained at near normal...

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment...

If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years...

MELBOURNE – 24 October 2024 – Two scientists have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. They are developing...

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024...

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL...

As we approach the OPTIONS XII for the Control of Influenza, a global scientific meeting that focuses on influenza, there is an enormous sense of pride among all of us at CSL Seqirus. For the...

Veltassa® offers effective and well-tolerated long-term potassium control in chronic kidney disease and chronic heart failure patients 1-5 Zeria Pharmaceutical Co., Ltd. to market Veltassa® in Japan

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®,...

CSL Seqirus to provide 665,000 pre-pandemic (zoonotic) vaccines to support fifteen EU and EEA Member States. Outbreaks of highly pathogenic avian influenza (HPAI) viruses in birds and poultry have...

Throughout 2023 and 2024, outbreaks of highly pathogenic avian influenza (HPAI) viruses among birds have been reported in several regions including Africa, Asia, Europe, and North America...

Data follow the approval of the world's first self-amplifying (sa-mRNA) COVID-19 vaccine for adults in Japan. These results add to recently published data on ARCT-154 demonstrating superior...

Under the licensing and distribution agreement, CSL Seqirus will be responsible for applying for regulatory approval, reimbursement and commercialisation of neffyTM (adrenaline nasal spray) ARS...

First non-immunosuppressive therapy for the treatment of IgA Nephropathy (IgAN) approved in Europe Conditional marketing authorization is based on statistically significant and clinically...

Australia’s newest biotech incubator Jumar Bioincubator has officially opened its doors and revealed the first 16 innovative early-stage ventures to take up residency in its much-awaited Melbourne-based facility at an event officiated by Lord Mayor, Sally Capp AO.

CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of...